Analysts have been eager to weigh in on the Financial sector with new ratings on Boston Properties (BXP – Research Report), Veris Residential (VRE – Research Report) and BRT Apartments (BRT – Research Report).
Boston Properties (BXP)
Mizuho Securities analyst Vikram Malhotra maintained a Buy rating on Boston Properties on June 23 and set a price target of $135.00. The company’s shares closed last Monday at $91.78, close to its 52-week low of $88.02.
According to TipRanks.com, Malhotra is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Boston Properties with a $121.38 average price target, representing a 31.9% upside. In a report issued on June 22, Credit Suisse also initiated coverage with a Buy rating on the stock with a $108.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Veris Residential (VRE)
Deutsche Bank analyst Derek Johnston maintained a Hold rating on Veris Residential on June 22 and set a price target of $15.00. The company’s shares closed last Monday at $13.90, close to its 52-week low of $13.42.
According to TipRanks.com, Johnston is a 4-star analyst with an average return of
Veris Residential has an analyst consensus of Hold, with a price target consensus of $17.20, representing a 23.6% upside. In a report issued on June 23, Evercore ISI also maintained a Hold rating on the stock with a $15.00 price target.
BRT Apartments (BRT)
Colliers Securities analyst Barry Oxford maintained a Buy rating on BRT Apartments on June 23. The company’s shares closed last Monday at $22.10.
According to TipRanks.com, Oxford is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BRT Apartments with a $28.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BXP:
- SNAP Stock: Still Risky Due to Near-Term Headwinds
- AstraZeneca’s Enhertu Wins Approval in EU by CHMP
- Ladenburg Thalmann & Co. Thinks BiomX’s Stock is Going to Recover
- ProVen Growth and Income VCT plc: Total voting rights
- Entourage Health Announces $8.9 Million Upsize to Credit Facility and Implementation of Proposed Amendments to 8.5% Unsecured Convertible Debentures
